News | July 09, 2012

Cardionovum Begins In Vivo Testing of Paclitaxel-Coated Drug-Eluting Balloon

July 9, 2012 — Cardionovum GmbH announced it has initiated in vivo testing of its second drug-eluting balloon (DEB) Restore. The company is currently marketing a line of CE-marked paclitaxel-coated DEBs for coronary (Primus) and peripheral (Legflow) applications. Cardionovum is featured in the most recent issue of IN VIVO magazine.

The Restore family of DEBs is novel because of its fast, intense drug-release platform. Restore was developed for the clinically efficient and successful treatment of patients who come back for repeat anti-proliferative treatment of restenosis. Restore’s paclitaxel coating ensures a biocompatible drug transfer into the arterial tissue under avoidance of micro emboli, which are often observed after application of other DEBs.

“Our core competence is in medical coating technologies. Our mission is to develop an entirely new paradigm for the safest and clinically most effective local drug delivery to the arterial lesion site,” said Michael Orlowski, Ph.D., CEO of Cardionovum. “We believe that our novel approach to drug-coating is superior to existing products on the market, as we do not use plasticizer, nor uncontrollable toxic drug excipients, giving us a potentially dominant position in the emerging market for DEBs as first-line therapy for a wide variety of patients in need of coronary and peripheral vascular interventions.”

Cardionovum’s products are not available for sale in the United States.

For more information:

Related Content

Trial Data Shows Positive Predictive Results for Boston Scientific HeartLogic Heart Failure Diagnostic
News | Heart Failure| October 20, 2017
October 20, 2017 — Boston Scientific announced new data from the Multisensor Chronic Evaluation in Ambulatory Heart F
Cardiovascular Risk Significantly Higher in Women With Fatty Liver Disease
News | Womens Healthcare| October 20, 2017
Nonalcoholic fatty liver disease (NAFLD) is associated with significantly higher risk of subsequent cardiovascular...
Pregnancy-Related Heart Failure Strikes Black Women Twice as Often as Other Races
News | Womens Healthcare| October 19, 2017
African American women were found to be twice as likely to be diagnosed with peripartum cardiomyopathy as compared to...
MRI May Predict Neurological Outcomes for Cardiac Arrest Survivors
News | Sudden Cardiac Arrest| October 18, 2017
Magnetic resonance imaging (MRI)-based measurements of the functional connections in the brain can help predict long-...
Xarelto Significantly Reduces Major Cardioavascular Events in Stable CAD and PAD Patients
News | Pharmaceuticals| October 18, 2017
October 18, 2017 — Results from the pivotal Phase 3 COMPASS study found that the...
First Patient Enrolled in U.S. Arm of ALIVE Pivotal Heart Failure Trial
News | Heart Failure| October 17, 2017
October 17, 2017 — BioVentrix Inc. recently announced enrollment of the first patient in the U.S.
Low Mortality and Stroke Risks Displayed for Minimally Invasive Aortic Valve Replacements
News | Heart Valve Technology| October 11, 2017
An analysis of more than 1,000 minimally invasive aortic valve replacements and more than 400 additional associated...
New Evaluation Sends Low-Risk ER Chest Pain Patients Home Sooner
News | Cardiac Diagnostics| October 10, 2017
A new evaluation to determine whether emergency room patients with chest pain can go home and follow up with their...
News | Pharmaceuticals| October 04, 2017
October 4, 2017 — MyoKardia Inc.
Medtronic Announces Post-Market Study for CoreValve Evolut Pro System
News | Heart Valve Technology| October 02, 2017
Medtronic plc recently announced a new post-market clinical study to evaluate its CoreValve Evolut Pro valve in...
Overlay Init